Positive results with lenvatinib for the treatment of advanced medullary thyroid cancer in a phase II trial

被引：0
|
作者：
机构：
来源：
Nature Reviews Endocrinology | 2015年 / 11卷 / 11期
关键词：
D O I：
10.1038/nrendo.2015.157
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：632 / 632
相关论文
共 50 条
  • [41] Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial
    Ravaud, A.
    de la Fouchardiere, C.
    Courbon, F.
    Asselineau, J.
    Klein, M.
    Nicoli-Sire, P.
    Bournaud, C.
    Delord, J.
    Weryha, G.
    Catargi, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma
    de Groot, J. W. B.
    Zonnenberg, B. A.
    van Ufford-Mannesse, P. Quarles
    de Vries, M. M.
    Links, T. P.
    Lips, C. J. M.
    Voest, E. E.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (09): : 3466 - 3469
  • [43] A phase 2 study of neoadjuvant lenvatinib in locally advanced invasive thyroid cancer
    Ahmed, Amr Hesham Abdelhamid
    Russell, Marika D.
    Kyriazidis, Natalia
    Karcioglu, Amanda Silver
    Sherman, Eric Jeffrey
    Ho, Alan Loh
    Fagin, James A.
    Wong, Richard J.
    Busaidy, Naifa Lamki
    Zafereo, Mark E.
    Sadow, Peter
    Park, Jong Chul
    Wirth, Lori J.
    Randolph, Gregory W.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Phase Ib/II trial of lenvatinib plus pembrolizumab in advanced melanoma.
    Taylor, Matthew H.
    Vogelzang, Nicholas J.
    Cohn, Allen Lee
    Stepan, Daniel E.
    Shumaker, Robert Charles
    Dutcus, Corina E.
    Guo, Matthew
    Schmidt, Emmett V.
    Rasco, Drew W.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [45] Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial
    Ranson, MR
    Carmichael, J
    OByrne, K
    Stewart, S
    Smith, D
    Howell, A
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (10) : 3185 - 3191
  • [46] MEDULLARY THYROID CANCER (MTC) : RESULTS OF TAILORED TREATMENT.
    Andry, G.
    RADIOTHERAPY AND ONCOLOGY, 2011, 98 : S30 - S31
  • [47] Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study
    Cohen, Ezra E. W.
    Rosen, Lee S.
    Vokes, Everett E.
    Kies, Merrill S.
    Forastiere, Arlene A.
    Worden, Francis P.
    Kane, Madeleine A.
    Sherman, Eric
    Kim, Sinil
    Bycott, Paul
    Tortorici, Michael
    Shalinsky, David R.
    Liau, Katherine F.
    Cohen, Roger B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) : 4708 - 4713
  • [48] Management of advanced medullary thyroid cancer
    Hadoux, Julien
    Pacini, Furio
    Tuttle, R. Michael
    Schlumberger, Martin
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (01): : 64 - 71
  • [49] A phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer.
    Wells, S.
    You, Y. N.
    Lakhani, V.
    Hou, J.
    Langmuir, P.
    Headley, D.
    Skinner, M.
    Morse, M.
    Burch, W.
    Schlumberger, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 288S - 288S
  • [50] Lenvatinib: a new option for the treatment of advanced iodine refractory differentiated thyroid cancer?
    Lorusso, Loredana
    Newbold, Kate
    FUTURE ONCOLOGY, 2015, 11 (12) : 1719 - 1727
12345